Drug-Eluting Balloons versus Second-Generation Drug-Eluting Stents for Treating In-Stent Restenosis in Coronary Heart Disease after PCI: A Meta-Analysis

Table 1

Characteristics of the included studies.

Trial (year)	Treatment and no. of patients ()		BMS- or DES-ISR	Type of the device		Study type	DAPT protocol	CAG F/U	Clinical F/U	MACE definition	Endpoint
				DEB	DES
Marquis-Gravel et al. [14]	100	102	Canadian all comers	Paclitaxel	2nd generation	Observational	NR	NR	15 months	Death (all), nonfatal MI, TLR	Restenosis, MACE, stroke/TIA
Adriaenssens et al. [15]	25	25	Belgium BMS	Paclitaxel	Everolimus	RCT	3 months for DEB	9 months	12 months	Death (all), MI, TVR	% of struts uncovered, DS%, LLL, MLD, MACE
							12 months for DES
Alfonso et al. [16]	95	94	Spain BMS	Paclitaxel	Everolimus	RCT	3 months for DEB	9 months	12 months	CD, MI, TVR	Death (all), TLR, MACE
							12 months for DES
Almalla et al. [17]	46	40	Germany DES	Paclitaxel	Everolimus	Observational	NR	NR	DEB: 25 months	Death (all), MI, TVR	MACE, TLR, ST, MACE rate
									DES: 22 months
Naganuma et al. [18]	73	85	Italy bifurcation ISR	Paclitaxel	Everolimus/zotarolimus	Observational	NR	NR	23 months	CD, MI, TVR	TLR, MACE
Kubo et al. [19]	37	52	Japan recurrent ISR after DEB	Paclitaxel	Everolimus	Observational	3 months for PCB	6–8 months	24 months	NR	ACM, CD, nonfatal MI, ST, TLR, MLD
							12 months for DES
Alfonso et al. [20]	154	155	Spain DES-ISR	Paclitaxel	Everolimus	RCT	3 months for DEB	6–9 months	12 months	CD, MI, TVR	MLD, MACE
							12 months for DES
Kang et al. [21]	182	56	DES	SeQuent Please	Everolimus	Observational	1 month for DCB	NR	24 months	CD, nonfatal MI, TVR	MACE
							12 months for DES
Basavarajaiah et al. [22]	81	166	DES	Paclitaxel	2nd generation	Observational	1 month for DCB	NR	12 months	CD, MI, TVR	Death (all), TLR, ST, MACE
							12 months for DES
Kawamoto et al. [23]	65	68	BMS- or DES-ISR	In.Pact Falcon	2nd generation	Observational	1 month for DEB	NR	12–24 months	ACM, MI, TLR	ST, MACE
				Pantera Lux			12 months for DES
Pleva et al. [24]	68	68	BMS	Paclitaxel	Everolimus	RCT	3 months for DEB	12 months (±2 months)	6 months, 12 months	ACM, any MI, AR	LLL, BR, ST, MACE
							6–12 months for DES
Cui et al. [25]	74	109	DES	SeQuent Please	2nd generation	Observational	3 months for DEB	NR	12 months	CD, nonfatal MI, TVR	MACE, no-event survival rate, ACM, TLR
							12 months for DES

DEB: drug-eluting balloon; DES: drug-eluting stent; BMS: bare-metal stent; ISR: in-stent restenosis; RCT: randomized controlled trial; DAPT: dual antiplatelet therapy; CAG: coronary angiography; F/U: follow-up; N/A: not applicable; MACE: major adverse cardiac event; CD: cardiac death; ACM: all-cause mortality; MI: myocardial infarction; ST: stent thrombosis; TVR: target vessel revascularization; TLR: target lesion revascularization; MLD: minimum luminal diameter; LLL: late lumen loss; PCB: paclitaxel-coated balloon.